The efficacy and safety of thrombopoietin-receptor agonists (TRAs) in elderly patients with primary immune thrombocytopenia (ITP) is uncertain. In 384 ITP patients treated with TRAs when aged ≥60 years, we investigated TRAs response and switch, thrombotic/hemorrhagic risk, and sustained responses off-treatment (SROT). After 3 months, 82.5% and 74.3% of eltrombopag and romiplostim-treated patients achieved a response, respectively (p=0.09); 66.7% maintained the response (median follow-up: 2.7 years). Eighty-five (22.2%) patients switched to the alternative TRA; while no cross-toxicity was observed, 83.3% of resistant patients had a response after the switch. During TRA, 34 major thromboses (3 fatal) and 14 major hemorrhages (none fatal) occurred in 18 and 10 patients, respectively, and were associated with thrombosis history (SHR: 2.04, p=0.05) and platelet count <20x109/L at TRA start (SHR: 1.69, p=0.04), respectively. A recurrent event occurred in 15.6% of patients surviving thrombosis, in all cases but one during persisting TRA treatment (incidence rate: 7.7 per 100 patient-years). All recurrences occurred in the absence of adequate antithrombotic secondary prophylaxis. Sixty-two (16.5%) responding patients discontinued TRA; 53 (13.8%) patients maintained SROT, which was associated with TRA discontinuation in complete response (p<0.001). Very old age (≥75, 41.1%) was associated with more frequent TRAs start in persistent/acute phase but not with response or thrombotic/hemorrhagic risk. TRAs are effective in elderly ITP patients, with no fatal haemorrhages and with SROT in a significant portion of patients; in patients with thrombosis history caution is warranted and a careful risk/benefit balance should be carried out.

Palandri, F., Rossi, E., Bartoletti, D., Ferretti, A., Ruggeri, M., Lucchini, E., Carrai, V., Barcellini, W., Patriarca, A., Rivolti, E., Consoli, U., Cantoni, S., Oliva, E. N., Chiurazzi, F., Caocci, G., Giuffrida, G., Borchiellini, A., Auteri, G., Baldacci, E., Carli, G., Nicolosi, D., Sutto, E., Carpenedo, M., Cavo, M., Mazzucconi, M. G., Zaja, F., De Stefano, V., Rodeghiero, F., Vianelli, N., Real-world use of thrombopoietin receptor agonists in elderly patients with primary immune thrombocytopenia, <<BLOOD>>, 2021; (N/A): N/A-N/A/A. [doi:10.1182/blood.2021010735] [http://hdl.handle.net/10807/178881]

Real-world use of thrombopoietin receptor agonists in elderly patients with primary immune thrombocytopenia

Rossi, Elena;De Stefano, Valerio
;
2021

Abstract

The efficacy and safety of thrombopoietin-receptor agonists (TRAs) in elderly patients with primary immune thrombocytopenia (ITP) is uncertain. In 384 ITP patients treated with TRAs when aged ≥60 years, we investigated TRAs response and switch, thrombotic/hemorrhagic risk, and sustained responses off-treatment (SROT). After 3 months, 82.5% and 74.3% of eltrombopag and romiplostim-treated patients achieved a response, respectively (p=0.09); 66.7% maintained the response (median follow-up: 2.7 years). Eighty-five (22.2%) patients switched to the alternative TRA; while no cross-toxicity was observed, 83.3% of resistant patients had a response after the switch. During TRA, 34 major thromboses (3 fatal) and 14 major hemorrhages (none fatal) occurred in 18 and 10 patients, respectively, and were associated with thrombosis history (SHR: 2.04, p=0.05) and platelet count <20x109/L at TRA start (SHR: 1.69, p=0.04), respectively. A recurrent event occurred in 15.6% of patients surviving thrombosis, in all cases but one during persisting TRA treatment (incidence rate: 7.7 per 100 patient-years). All recurrences occurred in the absence of adequate antithrombotic secondary prophylaxis. Sixty-two (16.5%) responding patients discontinued TRA; 53 (13.8%) patients maintained SROT, which was associated with TRA discontinuation in complete response (p<0.001). Very old age (≥75, 41.1%) was associated with more frequent TRAs start in persistent/acute phase but not with response or thrombotic/hemorrhagic risk. TRAs are effective in elderly ITP patients, with no fatal haemorrhages and with SROT in a significant portion of patients; in patients with thrombosis history caution is warranted and a careful risk/benefit balance should be carried out.
2021
Inglese
Palandri, F., Rossi, E., Bartoletti, D., Ferretti, A., Ruggeri, M., Lucchini, E., Carrai, V., Barcellini, W., Patriarca, A., Rivolti, E., Consoli, U., Cantoni, S., Oliva, E. N., Chiurazzi, F., Caocci, G., Giuffrida, G., Borchiellini, A., Auteri, G., Baldacci, E., Carli, G., Nicolosi, D., Sutto, E., Carpenedo, M., Cavo, M., Mazzucconi, M. G., Zaja, F., De Stefano, V., Rodeghiero, F., Vianelli, N., Real-world use of thrombopoietin receptor agonists in elderly patients with primary immune thrombocytopenia, <<BLOOD>>, 2021; (N/A): N/A-N/A/A. [doi:10.1182/blood.2021010735] [http://hdl.handle.net/10807/178881]
File in questo prodotto:
Non ci sono file associati a questo prodotto.

I documenti in IRIS sono protetti da copyright e tutti i diritti sono riservati, salvo diversa indicazione.

Utilizza questo identificativo per citare o creare un link a questo documento: https://hdl.handle.net/10807/178881
Citazioni
  • ???jsp.display-item.citation.pmc??? 2
  • Scopus 23
  • ???jsp.display-item.citation.isi??? 19
social impact